Recent studies revealed that Venetoclax in addition to potently blocking BCL-2 causes cellular responses that support anti-tumor activity including metabolic reprogramming and activation of the integrated stress response (Roca-Portoles et al, 2020; Weller et al, 2022). The gene discussed is BCL2; the disease is neoplasm.